Medications for opioid use disorders: clinical and pharmacological considerations.
作者信息
Volkow Nora D, Blanco Carlos
出版信息
J Clin Invest. 2020 Jan 2;130(1):10-13. doi: 10.1172/JCI134708.
Abstract
摘要
相似文献
1
Medications for opioid use disorders: clinical and pharmacological considerations.用于阿片类物质使用障碍的药物：临床及药理学考量
J Clin Invest. 2020 Jan 2;130(1):10-13. doi: 10.1172/JCI134708.
2
Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.接受丁丙诺啡、美沙酮或纳曲酮维持治疗的阿片类物质使用障碍患者的围手术期注意事项
Anesthesiol Clin. 2018 Sep;36(3):345-359. doi: 10.1016/j.anclin.2018.04.002. Epub 2018 Jul 11.
3
Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.美沙酮、丁丙诺啡和纳曲酮用于治疗孕妇阿片类物质使用障碍
Pharmacotherapy. 2017 Jul;37(7):824-839. doi: 10.1002/phar.1958. Epub 2017 Jul 2.
4
Medication-Assisted Treatment for Opioid-Use Disorder.阿片类物质使用障碍的药物辅助治疗。
Mayo Clin Proc. 2019 Oct;94(10):2072-2086. doi: 10.1016/j.mayocp.2019.03.029. Epub 2019 Sep 19.
5
Overview of Drugs Used to Treat Opioid Use Disorder.用于治疗阿片类物质使用障碍的药物概述。
Am J Nurs. 2018 Aug;118(8):25. doi: 10.1097/01.NAJ.0000544161.29445.db.
6
7
Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone.丁丙诺啡的II期临床试验：脱毒及纳曲酮诱导治疗
NIDA Res Monogr. 1992;121:101-19.
8
Medications for management of opioid use disorder.阿片类药物使用障碍的药物治疗。
Am J Health Syst Pharm. 2019 Jul 18;76(15):1097-1103. doi: 10.1093/ajhp/zxz105.
9
Clinical treatment of opioid addiction and dependence.阿片类药物成瘾和依赖的临床治疗。
Methods Mol Med. 2003;84:285-95. doi: 10.1385/1-59259-379-8:285.
10
Help Is on the Way: Medicare Coverage of Opioid Treatment Programs.援助即将到来：医疗保险覆盖阿片类药物治疗计划。
J Am Geriatr Soc. 2020 Mar;68(3):637-640. doi: 10.1111/jgs.16281. Epub 2019 Dec 11.
引用本文的文献
1
Exploring the therapeutic potential of psychedelics in treating substance use disorders.探索迷幻药在治疗物质使用障碍方面的治疗潜力。
Mol Psychiatry. 2025 Aug 19. doi: 10.1038/s41380-025-03168-w.
2
The synthetic opioid fentanyl increases HIV replication in macrophages.合成阿片类药物芬太尼会增加巨噬细胞中的HIV复制。
PLoS One. 2025 Feb 27;20(2):e0298341. doi: 10.1371/journal.pone.0298341. eCollection 2025.
3
Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open-label, non-randomised trial of long-acting injectable buprenorphine treatment in Australian custodial settings.参与澳大利亚羁押场所长效注射用丁丙诺啡治疗开放标签、非随机试验的阿片类药物使用障碍患者的治疗满意度和患者报告结局
Drug Alcohol Rev. 2025 Feb;44(2):640-648. doi: 10.1111/dar.14005. Epub 2025 Feb 3.
4
Understanding MAT access in the context of unused MAT capacity in the United States: when increasing rural MAT capacity is not enough.在美国未使用的药物辅助治疗（MAT）能力背景下理解MAT的可及性：增加农村地区MAT能力为何不足。
Subst Abuse Treat Prev Policy. 2024 Dec 20;19(1):47. doi: 10.1186/s13011-024-00628-4.
5
Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability.重新审视地佐辛用于阿片类药物使用障碍：对其潜在滥用倾向的叙述性综述。
CNS Neurosci Ther. 2024 Sep;30(9):e70034. doi: 10.1111/cns.70034.
6
Efficacy of transdermal buprenorphine patch for managing withdrawal symptoms in patients with cancer physically dependent on prescription opioids.经皮丁丙诺啡贴片治疗对处方阿片类药物躯体依赖的癌症患者戒断症状的疗效。
Oncologist. 2024 Nov 4;29(11):e1593-e1603. doi: 10.1093/oncolo/oyae176.
7
At a Crossroads: Opioid Use Disorder, the X-Waiver, and the Road Ahead.处于十字路口：阿片类物质使用障碍、X豁免权及未来之路
Ochsner J. 2024 Summer;24(2):108-117. doi: 10.31486/toj.23.0074.
8
Model of negative affect induced by withdrawal from acute and chronic morphine administration in male mice.雄性小鼠急性和慢性吗啡戒断引起的负性情绪模型。
Sci Rep. 2024 Apr 29;14(1):9767. doi: 10.1038/s41598-024-60759-3.
9
Vaccines to Treat Substance Use Disorders: Current Status and Future Directions.用于治疗物质使用障碍的疫苗：现状与未来方向
Pharmaceutics. 2024 Jan 8;16(1):84. doi: 10.3390/pharmaceutics16010084.
10
Targeting mitochondrial dynamics of morphine-responsive dopaminergic neurons ameliorates opiate withdrawal.靶向吗啡反应性多巴胺能神经元的线粒体动态改善阿片类戒断。
J Clin Invest. 2024 Jan 18;134(5):e171995. doi: 10.1172/JCI171995.
本文引用的文献
1
Buprenorphine in the United States: Motives for abuse, misuse, and diversion.丁丙诺啡在美国：滥用、误用和转移的动机。
J Subst Abuse Treat. 2019 Sep;104:148-157. doi: 10.1016/j.jsat.2019.07.005. Epub 2019 Jul 12.
2
Management of opioid use disorder in the USA: present status and future directions.美国阿片类药物使用障碍的管理：现状与未来方向。
Lancet. 2019 Apr 27;393(10182):1760-1772. doi: 10.1016/S0140-6736(18)33078-2. Epub 2019 Mar 14.
3
Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies.改善在提供医生和其他卫生服务的诊所（现场）接受美沙酮剂量的患者的治疗保留率，而不是在社区（场外）药房进行剂量治疗。
Drug Alcohol Depend. 2018 Oct 1;191:1-5. doi: 10.1016/j.drugalcdep.2018.04.029. Epub 2018 May 31.
4
Neurobiology of addiction: a neurocircuitry analysis.成瘾的神经生物学：神经回路分析
Lancet Psychiatry. 2016 Aug;3(8):760-773. doi: 10.1016/S2215-0366(16)00104-8.
5
Dynorphin, Dysphoria, and Dependence: the Stress of Addiction.强啡肽、烦躁不安与成瘾：成瘾的压力
Neuropsychopharmacology. 2016 Jan;41(1):373-4. doi: 10.1038/npp.2015.258.
6
A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.丁丙诺啡转移与滥用综述：当前的证据基础及全球经验
J Addict Med. 2014 Sep-Oct;8(5):315-26. doi: 10.1097/ADM.0000000000000045.
7
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.丁丙诺啡维持治疗与安慰剂或美沙酮维持治疗用于阿片类物质依赖的比较
Cochrane Database Syst Rev. 2014 Feb 6;2014(2):CD002207. doi: 10.1002/14651858.CD002207.pub4.
8
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.注射用纳曲酮长效制剂治疗阿片类药物依赖：一项双盲、安慰剂对照、多中心随机试验。
Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9.
9
Addiction: beyond dopamine reward circuitry.成瘾：超越多巴胺奖赏回路。
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15037-42. doi: 10.1073/pnas.1010654108. Epub 2011 Mar 14.
10
Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction.细胞对慢性阿片类药物的神经适应性变化：耐受性、戒断反应与成瘾
Br J Pharmacol. 2008 May;154(2):384-96. doi: 10.1038/bjp.2008.100. Epub 2008 Apr 14.
Zotero 插件